Nutraceutix, Inc. (OTCBB:NUTX) has developed Cobactin E(TM), a proprietary strain of the bacteria Lactobacillus acidophilus that has been shown to inhibit the highly pathogenic Escherichia coli strain O157:H7 in vitro.

The Centers for Disease Control estimates that 73,000 cases of infection and 61 deaths in the United States can be attributed to E. coli O157:H7 each year. The majority of these infections have been from consumption of contaminated juice, meat and other food products.

"In independent in vitro laboratory studies conducted at Bio Research Laboratories, Nutraceutix's Lactobacillus acidophilus strain 1386 - 1, eliminated 99.29% of E. coli O157:H7 in cultured media", said Tanya Turner, Head Microbiologist at Nutraceutix and developer of the strain, "This is confirmation of our internal research and sets the stage for further work in this area".

Lactobacillus acidophilus is an enrichment component of milk, yogurt and animal feeds as well as a common health supplement. Nutraceutix is one of the few manufacturers of lactic acid bacteria for these purposes in the U.S. These microorganisms are referred to as Probiotics.

"Probiotics will become more visible as major food companies introduce functional foods highlighting the inclusion of probiotics," said Bill St. John, Chairman of Nutraceutix, "In our research we are just beginning to tap the potential of probiotics for maintenance of health and prevention of infections."

In March 2000, Nutraceutix announced the development of the BioTract(TM) probiotic strain of lactobacillus salvarius, BT2070, which inhibits Helicobactor pylori, a causative agent of ulcers. In June of 1999, Nutraceutix announced the development of BaCCine(TM) probiotic culture, a strain of Lactococcus lactis shown in laboratory studies to be inhibitory to Listeria monocytogenes, the primary pathogen associated with Listeria food poisoning.

Except for any historical information, the matters discussed in this press release contain forward-looking statements, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statement.

Nutraceutix, Inc.RN develops, licenses and manufactures proprietary and non-proprietary private-label health supplements and related products for major health supplement companies, with distribution to health food retailers, multi-levels, and mass merchants. Nutraceutix also manufactures products for major brands utilizing proprietary processes of Controlled Delivery Technology (CDT(TM)), Molecular Dispersion Technology (MDT(TM)), PureTab(TM) Organic tableting, Cool-Tab(TM) and Live-Bac® probiotic caplets, as well as health supplement products containing the patented compound Calcium D-Glucarate(TM). Nutraceutix's fermentation facility is located at corporate headquarters where it also conducts research and development for the continued development of new health supplements for humans. Nutraceutix's private-label tableting, encapsulating and packaging facility is located outside Boulder, Colorado.